ARCH Capital
ARCH资本
ARCH Venture Partners, commonly referred to as ARCH Capital, is a U.S.-based venture firm widely regarded as a pioneer of the venture-studio model in life sciences. Founded in the 1980s by Steve Lazarus, then associate dean at Chicago Booth, it began with a $9 million first fund that backed 12 projects—four went public, four were acquired, and four were written off . The firm specializes in commercializing research from academic institutions and national laboratories, notably Argonne National Laboratory and the University of Chicago, and has incubated landmark companies including gene-sequencing leader Illumina and RNA-therapeutics developer Alnylam Pharmaceuticals . More recently, it has continued to back scientist-founded startups such as AIRNA, an RNA-editing therapeutics company established under its support .
AI-generated — may contain errors, please verify.
Coverage
Venture Studio: When Investors Become Startup Producers | He Lan on Entrepreneurship
Step Forward, Step Inside
AIRNA Closes $90 Million Series A to Advance Novel RNA-Editing Therapeutics
Accelerate the advancement of best-in-class drug candidates into clinical trials.
A Green Paper for VC Practitioners in an Era of Upheaval | 5Y View
Finding, discovering, and backing true innovators is what 5Y Capital has focused on for years, and it's also the standard we hold ourselves to as we continue to evolve.
Vitaeon Therapeutics Completes $200 Million Series B Round to Develop Transformative Therapies for Aging-Related Degenerative Diseases
Transforming the treatment paradigm for age-related degenerative diseases, improving quality of life for millions of patients and families worldwide.
3 Biopharma Companies Raise Over 1 Billion Yuan Combined | FreeS Family Funding News · October–November
Firmly bullish on the development of biomedical innovation in China
